The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global epigenetics market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 16% during 2021-2026.
Epigenetics refers to the study of heritable changes in the expression of active and inactive genes. The sources of changes can be both external from environmental factors or internal factors, such as age and disease. It is commonly used for the diagnosis of underlying conditions and preventing them from getting transferred to the future generations. It involves the use of various enzymes, instruments, such as sequencers, spectrometers and sonicators, reagents and kits. They are commonly utilized for deoxyribonucleic acid (DNA) and histone methylation, non-coding ribonucleic acid (RNA), acetylation and phosphorylation. As a result, epigenetics is widely used for the diagnosis, monitoring and treatment of oncological, autoimmune, metabolic, cardiovascular and pain disorders.
The increasing prevalence of cancer and autoimmune deficiency syndrome (AIDS) across the globe is among the key factors driving the market growth. Moreover, the widespread adoption of epigenetic solutions for non-oncological ailments is providing a thrust to the market growth. The sudden outbreak of the coronavirus disease (COVID-19) is also providing growth opportunities to market players. For instance, various research institutes are running advanced epigenetic tests to study the impact of the virus on the human genome and are developing tools for early recognition, risk evaluations and developing personalized treatments. Additionally, the development of DNA and RNA modifying enzymes, such as acetylases, methyltransferases, reverse transcriptase and ligases, and the launch of highly sensitive and selective tests and instruments, are acting as other growth-inducing factors. These innovations facilitate the assessment of locus-specific DNA methylation on a genome. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global epigenetics market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product, technology and application.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Technology, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at